2 Biotech Stocks That Could Make You Richer

Motley Fool2022-02-03

Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

565

Report

Comment（41）

jayfalcon
·2022-02-04
Like pls 🙏 thanks
Reply
Like
Report
AE2
·2022-02-03
Thanks for sharing
Reply
Like
Report
Gladys80
·2022-02-03
👍
Reply
Like
Report
JaiVenky
·2022-02-03
Nice
Reply
1
Report
Shirley Soh
·2022-02-03
Thanks
Reply
1
Report
riel.
·2022-02-03
comment
Reply
1
Report
SanWangtikup
·2022-02-03
Thanks
Reply
1
Report
hpt
·2022-02-03
Ok
Reply
3
Report
SafetyFirst
·2022-02-03
Ok
Reply
6
Report
78887480
·2022-02-03
Like pls thanks
Reply
1
Report
CIG
·2022-02-03
I bought EXEL at 18+ and kept waiting.
Reply
3
Report
JcJc
·2022-02-03
Maybe Yes ! Need to HOLD for 10 or 18 years 😅
Reply
2
Report
darrenlsw
·2022-02-03
Sure or not?
Reply
3
Report
Chororo
·2022-02-03
。
Reply
3
Report
Annie_ann29
·2022-02-03
Like plz
Reply
1
Report
TTS Sam
·2022-02-03
Good
Reply
5
Report
Linnleo
·2022-02-03
Nice
Reply
2
Report
sheenayam
·2022-02-03
Good
Reply
4
Report
V K
·2022-02-03
Pls like tyvm[Happy]
Reply
4
Report
BerryNat
·2022-02-03
Huat ah!
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1196109622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-03 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196109622","market":"us","top_or_hot":-1,"title":"2 Biotech Stocks That Could Make You Richer","media":"Motley Fool","content":"<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","article_id":"1196109622","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","pubTimestamp":1643852105,"sourceInfo":null,"weMediaInfo":null,"summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯","BLUE":"bluebird bio Inc."},"translate_title":"2种能让你更富有的生物科技股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLUE":0.9,"EXEL":0.9},"content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9091440820,"gmtCreate":1643933834075,"gmtModify":1676533872855,"author":{"id":"4090418835913750","authorId":"4090418835913750","name":"jayfalcon","avatar":"https://static.tigerbbs.com/505029b8d840d52745c57c2cbf910d5c","vip":1,"crmLevel":3,"crmLevelSwitch":1,"authorIdStr":"4090418835913750","idStr":"4090418835913750"},"htmlText":"Like pls 🙏 thanks","listText":"Like pls 🙏 thanks","text":"Like pls 🙏 thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091440820","repostId":1196109622,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091504350,"gmtCreate":1643892714160,"gmtModify":1676533868319,"author":{"id":"4104406149093920","authorId":"4104406149093920","name":"AE2","avatar":"https://community-static.tradeup.com/news/936b603ad820012fc76e5eb573cd7224","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"4104406149093920","idStr":"4104406149093920"},"htmlText":"Thanks for sharing","listText":"Thanks for sharing","text":"Thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091504350","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091508868,"gmtCreate":1643891486150,"gmtModify":1676533868221,"author":{"id":"4087907126409640","authorId":"4087907126409640","name":"Gladys80","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087907126409640","idStr":"4087907126409640"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091508868","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091268527,"gmtCreate":1643877764100,"gmtModify":1676533866810,"author":{"id":"3585210617348402","authorId":"3585210617348402","name":"JaiVenky","avatar":"https://static.tigerbbs.com/097793f3135b5fb8cb3f03847d72bf1a","vip":1,"crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3585210617348402","idStr":"3585210617348402"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091268527","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091268256,"gmtCreate":1643877748904,"gmtModify":1676533866803,"author":{"id":"4100664503126340","authorId":"4100664503126340","name":"Shirley Soh","avatar":"https://community-static.tradeup.com/news/784ec5f33096066f43c22d219e548bac","vip":1,"crmLevel":8,"crmLevelSwitch":1,"authorIdStr":"4100664503126340","idStr":"4100664503126340"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091268256","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091261690,"gmtCreate":1643877488716,"gmtModify":1676533866779,"author":{"id":"4098107507332990","authorId":"4098107507332990","name":"riel.","avatar":"https://static.tigerbbs.com/93af5f5222961974cc81ff1226161491","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4098107507332990","idStr":"4098107507332990"},"htmlText":"comment","listText":"comment","text":"comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091261690","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091287303,"gmtCreate":1643876608211,"gmtModify":1676533866662,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087452914358580","idStr":"4087452914358580"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091287303","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091283249,"gmtCreate":1643873626084,"gmtModify":1676533866506,"author":{"id":"3579759306103275","authorId":"3579759306103275","name":"hpt","avatar":"https://static.tigerbbs.com/986ef7c951112f7be64cfd5d6c1672c5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3579759306103275","idStr":"3579759306103275"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091283249","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091289102,"gmtCreate":1643872566513,"gmtModify":1676533866490,"author":{"id":"3570965583958757","authorId":"3570965583958757","name":"SafetyFirst","avatar":"https://static.tigerbbs.com/a6356c1a4c82b1755621f3b2631a6784","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3570965583958757","idStr":"3570965583958757"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091289102","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091280276,"gmtCreate":1643872269422,"gmtModify":1676533866453,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4106832071804060","idStr":"4106832071804060"},"htmlText":"Like pls thanks","listText":"Like pls thanks","text":"Like pls thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280276","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091217299,"gmtCreate":1643871870180,"gmtModify":1676533866436,"author":{"id":"3583974841960176","authorId":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3583974841960176","idStr":"3583974841960176"},"htmlText":"I bought EXEL at 18+ and kept waiting.","listText":"I bought EXEL at 18+ and kept waiting.","text":"I bought EXEL at 18+ and kept waiting.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091217299","repostId":1196109622,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091217322,"gmtCreate":1643871712421,"gmtModify":1676533866444,"author":{"id":"4088126420960140","authorId":"4088126420960140","name":"JcJc","avatar":"https://static.tigerbbs.com/3a18de000ce7013be088f3ab4082bd27","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4088126420960140","idStr":"4088126420960140"},"htmlText":"Maybe Yes ! Need to HOLD for 10 or 18 years 😅","listText":"Maybe Yes ! Need to HOLD for 10 or 18 years 😅","text":"Maybe Yes ! Need to HOLD for 10 or 18 years 😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091217322","repostId":1196109622,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091297546,"gmtCreate":1643866014888,"gmtModify":1676533865809,"author":{"id":"3574260792698407","authorId":"3574260792698407","name":"darrenlsw","avatar":"https://community-static.tradeup.com/news/146979aca2cc98520f97f1472521789b","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3574260792698407","idStr":"3574260792698407"},"htmlText":"Sure or not?","listText":"Sure or not?","text":"Sure or not?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091297546","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091294422,"gmtCreate":1643865724458,"gmtModify":1676533865793,"author":{"id":"3548890322785063","authorId":"3548890322785063","name":"Chororo","avatar":"https://static.tigerbbs.com/0cbcbb673621a63bd8bb2f8219eded23","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3548890322785063","idStr":"3548890322785063"},"htmlText":"。","listText":"。","text":"。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091294422","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091294665,"gmtCreate":1643865683584,"gmtModify":1676533865785,"author":{"id":"4088678216292640","authorId":"4088678216292640","name":"Annie_ann29","avatar":"https://static.tigerbbs.com/74b75bf973f051fd1f70b054cc66a45c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4088678216292640","idStr":"4088678216292640"},"htmlText":"Like plz","listText":"Like plz","text":"Like plz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091294665","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091295003,"gmtCreate":1643865343186,"gmtModify":1676533865744,"author":{"id":"4089928668743000","authorId":"4089928668743000","name":"TTS Sam","avatar":"https://static.tigerbbs.com/6a204098417c49dc0ecd7d4a76a72459","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4089928668743000","idStr":"4089928668743000"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091295003","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091207483,"gmtCreate":1643863726041,"gmtModify":1676533865563,"author":{"id":"3584658134750205","authorId":"3584658134750205","name":"Linnleo","avatar":"https://static.tigerbbs.com/b57e83af12c17b31db1fb1b80ea44c6a","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584658134750205","idStr":"3584658134750205"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091207483","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091201910,"gmtCreate":1643862526894,"gmtModify":1676533865366,"author":{"id":"3579743164156658","authorId":"3579743164156658","name":"sheenayam","avatar":"https://static.tigerbbs.com/fe1b57a8371314fd64ce0840001df6b2","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3579743164156658","idStr":"3579743164156658"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091201910","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091677251,"gmtCreate":1643861967595,"gmtModify":1676533865274,"author":{"id":"3577323914202336","authorId":"3577323914202336","name":"V K","avatar":"https://static.tigerbbs.com/536d624e5750dcffec704eeed9bc003b","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3577323914202336","idStr":"3577323914202336"},"htmlText":"Pls like tyvm[Happy]&nbsp;","listText":"Pls like tyvm[Happy]&nbsp;","text":"Pls like tyvm[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091677251","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9091673969,"gmtCreate":1643860251085,"gmtModify":1676533865076,"author":{"id":"4087986020499840","authorId":"4087986020499840","name":"BerryNat","avatar":"https://static.tigerbbs.com/27333e490249edd9b1054f0311c8584c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087986020499840","idStr":"4087986020499840"},"htmlText":"Huat ah!","listText":"Huat ah!","text":"Huat ah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091673969","repostId":1196109622,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":565,"commentSize":41,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false}}